What is small cell carcinoma of the ovary, hypercalcaemic type?
Small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) is a very rare and aggressive ovarian cancer. Unlike most ovarian cancers, it mainly affects girls and young women, with an average age at diagnosis of about 24 years (Young, Oliva and Scully, 1994).
The name comes from two features. Under the microscope the cancer is made up of small, tightly packed cells. In about two-thirds of patients, the tumour also causes a high level of calcium in the blood (hypercalcaemia).
Almost all cases are caused by loss of a gene called SMARCA4. This gene normally helps to control how DNA is packaged and read (Witkowski et al., 2014).
Because SCCOHT is so rare, many specialists now regard it as a rhabdoid tumour of the ovary. It is related to the rhabdoid tumours that occur in the brain and kidneys of young children.
Treatment usually combines surgery, intensive chemotherapy and sometimes radiotherapy. Women and girls with SCCOHT, and their families, are offered genetic testing.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Undifferentiated, rhabdoid-like ovarian cancer |
| How common | Very rare; under 1% of ovarian cancers |
| Typical age | Average about 24; range from early childhood to the mid-40s |
| Key gene | SMARCA4 loss in over 90% |
| Inherited cases | Germline SMARCA4 variants in a substantial minority |
| Raised calcium | About two-thirds of patients |
| Usual sides | Almost always one ovary |
| Main treatment | Surgery and intensive chemotherapy, with radiotherapy or high-dose chemotherapy in some |
| Outlook | Serious; best when the cancer is confined to one ovary |
2. Causes and risk factors
In nearly every case of SCCOHT, both copies of the SMARCA4 gene are switched off in the tumour cells (Ramos et al., 2014; Jelinic et al., 2014).
SMARCA4 makes a protein called BRG1. BRG1 is part of the SWI/SNF complex, a group of proteins that open and close DNA so that genes can be turned on or off. Without it, cells lose control of growth and stay immature.
| Factor | Details |
|---|---|
| Germline SMARCA4 variant | Inherited from a parent or arising new; found in a significant minority of patients |
| Family history | Some families have several young women with SCCOHT |
| Age | Mainly girls and women under 40 |
People with a germline SMARCA4 variant have rhabdoid tumour predisposition syndrome type 2. This raises the risk of SCCOHT and, less often, of other rhabdoid tumours.
Other risk factors linked with ovarian cancer, such as BRCA genes, endometriosis or older age, do not apply to SCCOHT.
Genetic counselling
Every patient with SCCOHT should be offered genetic counselling and germline SMARCA4 testing (Tischkowitz et al., 2020).
If a variant is found, sisters and other relatives can be tested. Women who carry the variant may be offered surveillance or risk-reducing removal of the ovaries once they have completed their family.
3. How does it look
Under the microscope
SCCOHT is made of sheets of small, round blue cells with little cytoplasm and many dividing cells. Some tumours contain fluid-filled spaces that look like small follicles.
About half include a large-cell variant, with bigger cells and more pink cytoplasm. Some cells may have a rhabdoid look, with an off-centre nucleus.
The most useful test is staining for BRG1 (SMARCA4) protein. Loss of BRG1 in the tumour cells strongly supports the diagnosis.
The tumour itself
| Feature | Typical finding |
|---|---|
| Size | Usually large, often 10-15 cm or more |
| Sides | Almost always one ovary |
| Cut surface | Soft, fleshy, cream to tan, with areas of bleeding and dead tissue |
| Spread | About half have spread beyond the ovary at diagnosis |
On scans
Ultrasound, CT and MRI usually show a large, solid or mixed solid-cystic mass in the pelvis. Scans may also reveal fluid in the abdomen (ascites), deposits on the lining of the abdomen and enlarged lymph nodes.
Visible signs
| Sign | What it looks like |
|---|---|
| Swollen abdomen | A visibly enlarged belly from the mass or fluid |
| Weight loss or thinner face and arms | In advanced disease |
| Signs of dehydration | Dry mouth and skin from high calcium causing frequent urination |
4. Symptoms
Symptoms are often non-specific and can be mistaken for more common problems in young women, such as cysts or digestive complaints.
Common symptoms
- Abdominal swelling or bloating
- Pain in the abdomen or pelvis
- A lump that can be felt in the lower abdomen
- Feeling full quickly after eating
- Nausea, vomiting or constipation
- Changes in periods, in some patients
- Tiredness and weight loss
Symptoms of high calcium
High calcium is often found on a blood test. It can, however, cause symptoms:
| Symptom | Description |
|---|---|
| Thirst and passing a lot of urine | Calcium affects the kidneys |
| Nausea and loss of appetite | Often with constipation |
| Tiredness and weakness | Muscles and nerves work less well |
| Confusion or low mood | With very high levels |
| Abdominal pain | Sometimes from pancreatitis or kidney stones |
The high calcium is caused by a hormone-like substance made by the tumour, called parathyroid hormone-related protein (PTHrP). Calcium usually returns to normal after the tumour is removed, and a rise in calcium can be an early sign of relapse.
When to seek medical advice
See a doctor promptly if you have persistent bloating, pelvic pain or a lump in the abdomen, even if you are young.
Seek urgent help for severe abdominal pain, vomiting, confusion or extreme thirst.
5. Diagnosis
| Test | Purpose |
|---|---|
| Pelvic ultrasound | First test for a pelvic mass |
| CT or MRI scan | Shows the size of the tumour and any spread |
| Blood calcium level | Raised in about two-thirds |
| Tumour markers | CA-125 may be raised; tests for germ cell tumours (AFP, hCG) are usually normal |
| Surgery and pathology | Confirms the diagnosis, including BRG1 staining |
| SMARCA4 testing | In the tumour and in blood for inherited variants |
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Adult granulosa cell tumour | Older women; FOXL2 change; slower growth |
| Juvenile granulosa cell tumour | Often makes hormones; BRG1 retained |
| Germ cell tumours (dysgerminoma) | Raised tumour markers; different stains |
| Small cell carcinoma, pulmonary type | Older women; neuroendocrine markers |
| Lymphoma | Lymphoid markers on staining |
Staging
SCCOHT is staged using the FIGO system for ovarian cancer, from stage I (confined to the ovary) to stage IV (spread outside the abdomen).
6. Treatment
Treatment should take place at a specialist gynaecological oncology centre, ideally one with experience of rare ovarian tumours and links with paediatric or sarcoma teams.
Surgery
| Option | Details |
|---|---|
| Complete staging surgery | Removal of the ovaries, fallopian tubes and womb, with sampling of lymph nodes and the abdominal lining |
| Removing all visible tumour | The aim in advanced disease |
| Fertility-sparing surgery | Removal of one ovary only; rarely advised because of the high risk of recurrence |
Experts usually recommend bilateral removal of the ovaries, even in young women. Fertility options, such as egg or embryo freezing, should be discussed before treatment where possible.
Chemotherapy
Most patients receive intensive combination chemotherapy after surgery (Callegaro-Filho et al., 2016; Tischkowitz et al., 2020).
| Approach | Details |
|---|---|
| Multi-drug regimens | For example vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin and etoposide (VPCBAE) |
| Platinum and etoposide | Used in some centres |
| High-dose chemotherapy with stem cell rescue | Considered after initial treatment in some patients to consolidate response |
Radiotherapy
Pelvic or whole-abdomen radiotherapy may be given after chemotherapy in some patients. Its role is still being studied.
Newer treatments
| Treatment | Status |
|---|---|
| EZH2 inhibitors (tazemetostat) | Studied in SMARCA4-deficient tumours |
| Immune checkpoint inhibitors | Responses reported in some patients |
| CDK4/6 inhibitors and other targeted drugs | Under research |
| Clinical trials | Recommended where available |
Why intensive treatment is used
SCCOHT can grow and spread within weeks. For this reason, doctors usually recommend treatment that is more intensive than for common ovarian cancers, even when the cancer appears to be confined to one ovary.
Treatment is demanding, and it is usually given over several months. The care team will discuss its benefits and side effects openly, including the effects on hormones, fertility and daily life.
Treating high calcium
High calcium is treated with fluids through a drip, medicines such as bisphosphonates and, most importantly, treating the tumour itself.
7. Outlook (prognosis)
SCCOHT has a serious outlook. Many tumours have spread by the time they are found, and relapse is common, often within the first two years.
| Factor | Effect |
|---|---|
| Stage IA (one ovary, intact capsule) | Best outlook; a proportion of patients are cured |
| Advanced stage | Long-term survival is uncommon |
| Complete removal of tumour | Better outlook |
| Intensive multimodal treatment | Associated with better survival in case series |
| Normal calcium before surgery and small tumour size | Linked with better outcomes in some studies |
Because the disease is rare, results come from small studies and registries. International collaboration, including the International SCCOHT Consortium and patient registries, is helping to define the best treatment. Patients are encouraged to share their information with these registries, as each case helps to improve care for future patients.
8. Follow-up and living with SCCOHT
After treatment, regular follow-up includes examination, blood tests (including calcium) and scans. Visits are often every 3 months for the first two years and then less often.
| Issue | Support available |
|---|---|
| Early menopause | Hormone replacement therapy is usually possible and helps protect bones and heart |
| Fertility loss | Counselling and fertility services |
| Emotional impact | Psychologists, specialist nurses and support groups for young adults with cancer |
| Family members | Genetic counselling and testing |
If the cancer comes back
A relapse is most often found within two years of treatment, in the abdomen or pelvis. A rising calcium level or new symptoms such as bloating and pain can be early signs.
Treatment options at relapse include further chemotherapy, surgery, radiotherapy and clinical trials of newer drugs. The aim may be to control the disease, relieve symptoms and maintain quality of life.
Fertility and hormones
Removing both ovaries causes an immediate menopause in girls and young women. Hormone replacement therapy is usually recommended until the natural age of menopause, unless there is a specific reason to avoid it.
Fertility specialists can discuss egg, embryo or ovarian tissue freezing before treatment. Pregnancy may later be possible using stored eggs or embryos, or donor eggs, if the womb has been kept.
9. Frequently asked questions
| Question | Answer |
|---|---|
| Is SCCOHT the same as other ovarian cancers? | No. It affects younger women, has a different genetic cause and is treated differently |
| Why is my calcium high? | The tumour makes a protein that raises calcium |
| Is it inherited? | Sometimes. Germline SMARCA4 testing is recommended for every patient |
| Can I keep my fertility? | Usually both ovaries are removed, but egg or embryo freezing may be possible beforehand |
| Should my sister be tested? | If you carry a SMARCA4 variant, close relatives can be offered testing |
| Is it related to small cell lung cancer? | No. Despite the similar name, SCCOHT is a different disease with a different cause |
| Where can I find support? | Specialist nurses, teenage and young adult cancer services and the Small Cell Ovarian Cancer Foundation |
10. Questions to ask your care team
- What stage is my cancer?
- Has BRG1 (SMARCA4) loss been confirmed?
- Will I have genetic testing, and what does it mean for my family?
- What treatment do you recommend, including high-dose chemotherapy?
- What are my fertility options?
- Are there clinical trials for SCCOHT?
- How will my calcium levels be monitored during and after treatment?
- Who will coordinate my care between the different specialist teams?
Resources
- Young, R.H., Oliva, E. and Scully, R.E. (1994) ‘Small cell carcinoma of the ovary, hypercalcemic type: a clinicopathological analysis of 150 cases’, American Journal of Surgical Pathology, 18(11), pp. 1102-1116.
- Witkowski, L. et al. (2014) ‘Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type’, Nature Genetics, 46(5), pp. 438-443.
- Ramos, P. et al. (2014) ‘Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4’, Nature Genetics, 46(5), pp. 427-429.
- Jelinic, P. et al. (2014) ‘Recurrent SMARCA4 mutations in small cell carcinoma of the ovary’, Nature Genetics, 46(5), pp. 424-426.
- Tischkowitz, M. et al. (2020) ‘Small-cell carcinoma of the ovary, hypercalcemic type – genetics, new treatment targets, and current management guidelines’, Clinical Cancer Research, 26(15), pp. 3908-3917.
- Callegaro-Filho, D. et al. (2016) ‘Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): a review of 47 cases’, Gynecologic Oncology, 140(1), pp. 53-57.
- Wade, I. et al. (2025) ‘Using cancer phenotype sex-specificity to enable unbiased penetrance estimation of SMARCA4 pathogenic variants for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)’, Genetics in Medicine, 27(1), p. 101287.
- Small Cell Ovarian Cancer Foundation (2026) Small Cell Ovarian Cancer Foundation. Available at: https://www.smallcellovarian.org/ (Accessed: October 2026).
Prepared by the editorial team, October 2026.